These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8372726)

  • 1. Tenidap--a new antiarthritic agent.
    Brooks PM
    Agents Actions Suppl; 1993; 44():161-3. PubMed ID: 8372726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts.
    Martel-Pelletier J; Mineau F; Tardif G; Fernandes JC; Ranger P; Loose L; Pelletier JP
    J Rheumatol; 1996 Jan; 23(1):24-31. PubMed ID: 8838504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. I. Mechanism and evidence of functional significance.
    McNiff P; Svensson L; Pazoles CJ; Gabel CA
    J Immunol; 1994 Sep; 153(5):2180-93. PubMed ID: 8051419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis.
    Ounissi-Benkalha H; Pelletier JP; Tardif G; Mineau F; Jolicoeur FC; Ranger P; Martel-Pelletier J
    J Rheumatol; 1996 Jan; 23(1):16-23. PubMed ID: 8838503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenidap.
    Madhok R
    Lancet; 1995 Aug; 346(8973):481-5. PubMed ID: 7637484
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of tenidap on canine experimental osteoarthritis: II. Study of the expression of collagenase-1 and interleukin 1beta by in situ hybridization.
    Fernandes JC; Martel-Pelletier J; Jovanovic D; Tardif G; DiBattista JA; Lascau-Coman V; Otterness IG; Pelletier JP
    J Rheumatol; 1998 May; 25(5):951-8. PubMed ID: 9598897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenidap, an anti-inflammatory agent, discharges intracellular Ca++ store and inhibits Ca++ influx in cultured human gingival fibroblasts.
    Fujii A; Matsumoto H; Hashimoto T; Akimoto Y
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1447-52. PubMed ID: 8531115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties.
    Moore PF; Larson DL; Otterness IG; Weissman A; Kadin SB; Sweeney FJ; Eskra JD; Nagahisa A; Sakakibara M; Carty TJ
    Inflamm Res; 1996 Feb; 45(2):54-61. PubMed ID: 8907585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis.
    Breedveld F
    Scand J Rheumatol Suppl; 1994; 100():31-44. PubMed ID: 7532319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of acute-phase proteins with tenidap sodium, a cytokine-modulating anti-rheumatic drug.
    Loose LD; Sipe JD; Kirby DS; Kraska AR; Weiner ES; Shanahan WR; Leeming MR; Farrow P; Stack CB; Ting N
    Br J Rheumatol; 1993 Jun; 32 Suppl 3():19-25. PubMed ID: 7685226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenidap versus diclofenac in rheumatoid arthritis.
    Swaak AJ
    Br J Rheumatol; 1996 Jun; 35(6):602. PubMed ID: 8673363
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical study of the efficacy of and tolerance for a new nonsteroidal anti-inflammatory agent, cinmetacin].
    Lucietti MV; Banchieri G
    G Clin Med; 1980 Jul; 61(7):545-52. PubMed ID: 7004981
    [No Abstract]   [Full Text] [Related]  

  • 15. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diclofenac/misoprostol: the European clinical experience.
    McKenna F
    J Rheumatol Suppl; 1998 May; 51():21-30. PubMed ID: 9596551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Tenidap (CP-66,248) on human neutrophil arachidonic acid metabolism, chemotactic potential and clinical efficacy in the treatment of rheumatoid arthritis.
    Smith DM; Johnson JA; Loeser R; Turner RA
    Agents Actions; 1990 Aug; 31(1-2):102-9. PubMed ID: 2126672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis.
    Hall VC; Wolf RE
    J Rheumatol; 1997 Aug; 24(8):1467-70. PubMed ID: 9263136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The homeopathic antiarthitic preparation Zeel comp. N: a review of molecular and clinical data.
    Birnesser H; Stolt P
    Explore (NY); 2007; 3(1):16-22. PubMed ID: 17234564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
    Infante R; Lahita RG
    Geriatrics; 2000 Mar; 55(3):30-2, 35-6, 39-40. PubMed ID: 10732003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.